502 related articles for article (PubMed ID: 26372098)
1. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
4. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
J Thorac Oncol; 2016 Aug; 11(8):1319-1325. PubMed ID: 27234604
[TBL] [Abstract][Full Text] [Related]
6. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
8. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
[TBL] [Abstract][Full Text] [Related]
9. Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
Zheng Y; Shi A; Wang W; Yu H; Yu R; Li D; Xu B; Ma H; You J; Zhao D; Jiang L; Geng J; Zhu G
Clin Lung Cancer; 2018 Jul; 19(4):e399-e404. PubMed ID: 29519614
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
12. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
Sebastian N; Wu T; Bazan J; Driscoll E; Willers H; Yegya-Raman N; Bond L; Dwivedi A; Mo X; Tan Y; Xu-Welliver M; Haglund K; Jabbour SK; Keane FK; Williams TM
Radiother Oncol; 2019 May; 134():151-157. PubMed ID: 31005209
[TBL] [Abstract][Full Text] [Related]
14. Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.
Hayes JT; David EA; Qi L; Chen AM; Daly ME
Clin Lung Cancer; 2015 Sep; 16(5):379-84. PubMed ID: 25737143
[TBL] [Abstract][Full Text] [Related]
15. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
Ueki N; Matsuo Y; Togashi Y; Kubo T; Shibuya K; Iizuka Y; Mizowaki T; Togashi K; Mishima M; Hiraoka M
J Thorac Oncol; 2015 Jan; 10(1):116-25. PubMed ID: 25376512
[TBL] [Abstract][Full Text] [Related]
16. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
Shi S; Ye L; Zhao Q; Hu Y; Huang Y; Chen G; Zeng Z; He J
Jpn J Clin Oncol; 2019 Apr; 49(4):367-372. PubMed ID: 30715411
[TBL] [Abstract][Full Text] [Related]
17. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
18. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
Suzuki R; Wei X; Allen PK; Cox JD; Komaki R; Lin SH
Clin Lung Cancer; 2019 Mar; 20(2):117-123. PubMed ID: 30611672
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Chang JY; Liu H; Balter P; Komaki R; Liao Z; Welsh J; Mehran RJ; Roth JA; Swisher SG
Radiat Oncol; 2012 Sep; 7():152. PubMed ID: 22963661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
